ITI 1020
Alternative Names: ITI-1020Latest Information Update: 07 Dec 2020
At a glance
- Originator Immunomic Therapeutics
- Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Glioblastoma
Most Recent Events
- 20 Nov 2020 Immunomic Therapeutics and CoImmune Therapeutics enter into partnership to manufacture ITI 1020 for Glioblastoma
- 20 Nov 2020 Early research in Glioblastoma (First-line therapy) in USA (Parenteral), prior to November 2020
- 20 Nov 2020 Immunomic Therapeutics announces intention to submit regulatory application for Glioblastoma